Will partnering in Europe be worthwhile for your company?

To help answer this question, we analyzed 43 licensing deals for pharmaceutical products in which Europe was the major territory for a foreign partner between January 2012 and August 2019.

Inside you will find discussion and graphs addressing:

• Total deal size;
• Upfront and equity payments;
• Development, commercial and total milestones;
• Royalties;
• Number of products in a deal;
• Therapeutic area and deal value;
• Phase of development and deal value;
• Type of technology;
• Nationality of licensee;
• Trends;
• Conclusions; and
• Methodology.

Sign-up below to gain access to the full report (PDF):